BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24747602)

  • 1. MicroRNAs as prognostic markers in ovarian cancer.
    Llauradó M; Majem B; Altadill T; Lanau L; Castellví J; Sánchez-Iglesias JL; Cabrera S; De la Torre J; Díaz-Feijoo B; Pérez-Benavente A; Colás E; Olivan M; Doll A; Alameda F; Matias-Guiu X; Moreno-Bueno G; Carey MS; Del Campo JM; Gil-Moreno A; Reventós J; Rigau M
    Mol Cell Endocrinol; 2014 Jun; 390(1-2):73-84. PubMed ID: 24747602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs in Ovarian Cancer.
    Katz B; Tropé CG; Reich R; Davidson B
    Hum Pathol; 2015 Sep; 46(9):1245-56. PubMed ID: 26216350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications.
    Mezzanzanica D; Bagnoli M; De Cecco L; Valeri B; Canevari S
    Int J Biochem Cell Biol; 2010 Aug; 42(8):1262-72. PubMed ID: 20035894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
    Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
    Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNAs in ovarian cancer biology and therapy resistance.
    van Jaarsveld MT; Helleman J; Berns EM; Wiemer EA
    Int J Biochem Cell Biol; 2010 Aug; 42(8):1282-90. PubMed ID: 20083225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
    Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
    Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of microRNAs in drug-resistant ovarian cancer cells.
    Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
    Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status on microRNAs as biomarkers for ovarian cancer.
    Prahm KP; Novotny GW; Høgdall C; Høgdall E
    APMIS; 2016 May; 124(5):337-55. PubMed ID: 26809719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs in malignant melanoma.
    Völler D; Ott C; Bosserhoff A
    Clin Biochem; 2013 Jul; 46(10-11):909-17. PubMed ID: 23360785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of microRNAs in melanoma.
    Luo C; Weber CE; Osen W; Bosserhoff AK; Eichmüller SB
    Eur J Cell Biol; 2014; 93(1-2):11-22. PubMed ID: 24602414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical and diagnostic role of microRNAs in ovarian carcinoma.
    Davidson B; Tropé CG; Reich R
    Gynecol Oncol; 2014 Jun; 133(3):640-6. PubMed ID: 24713546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miRNAs as molecular biomarkers of cancer.
    Fabbri M
    Expert Rev Mol Diagn; 2010 May; 10(4):435-44. PubMed ID: 20465498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
    Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-analytical variables in miRNA analysis.
    Becker N; Lockwood CM
    Clin Biochem; 2013 Jul; 46(10-11):861-8. PubMed ID: 23466658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of microRNAs in colorectal cancer.
    Liu M; Chen H
    J Genet Genomics; 2010 Jun; 37(6):347-58. PubMed ID: 20621017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.
    Hu X; Macdonald DM; Huettner PC; Feng Z; El Naqa IM; Schwarz JK; Mutch DG; Grigsby PW; Powell SN; Wang X
    Gynecol Oncol; 2009 Sep; 114(3):457-64. PubMed ID: 19501389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetically regulated microRNAs and their prospect in cancer diagnosis.
    Kita Y; Vincent K; Natsugoe S; Berindan-Neagoe I; Calin GA
    Expert Rev Mol Diagn; 2014 Jul; 14(6):673-83. PubMed ID: 24914586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression.
    Faggad A; Budczies J; Tchernitsa O; Darb-Esfahani S; Sehouli J; Müller BM; Wirtz R; Chekerov R; Weichert W; Sinn B; Mucha C; Elwali NE; Schäfer R; Dietel M; Denkert C
    J Pathol; 2010 Feb; 220(3):382-91. PubMed ID: 19960504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetics in ovarian cancer.
    Seeber LM; van Diest PJ
    Methods Mol Biol; 2012; 863():253-69. PubMed ID: 22359298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNA control of apoptotic programs: focus on ovarian cancer.
    Mezzanzanica D; Canevari S; Cecco LD; Bagnoli M
    Expert Rev Mol Diagn; 2011 Apr; 11(3):277-86. PubMed ID: 21463237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.